Davis Polk & Wardwell, Mayer Brown, and Mishcon de Reya advised Gilead, while Goodwin Procter and Wilson Sonsini Goodrich & Rosati advised MiroBio on the deal. […]
Gilead Sciences’ $405 Million Acquisition of MiroBio
Legend Biotech’s $403 Million Shares Offering
Davis Polk advised the underwriters in the offering. Legend Biotech Corporation executed its $403 million SEC-registered follow-on offering of 9,361,000 American depositary shares, each representing two ordinary […]
Revolution Medicines’ $230 Million Shares Offering
Latham & Watkins represented Revolution Medicines, while Davis Polk advised the underwriters in the offering. Revolution Medicines, Inc. (Nasdaq: RVMD), has announced the pricing of its underwritten […]
URUS’s $170 Million Acquisition of Trans Ova Genetics
Davis Polk advised Precigen on the deal. Precigen, Inc. executed the sale of its wholly-owned non-healthcare subsidiary, Trans Ova Genetics, L.C. (“Trans Ova”), an industry-leading animal […]
Applied Therapeutics’ $30 Million Stock and Warrants Offering
Davis Polk advised the underwriter, SVB Securities, in the offering. Applied Therapeutics, Inc. announced its offering of 20,000,000 shares of common stock, pre-funded warrants to purchase up […]
GSK’s $3.3 Billion Acquisition of Affinivax
Davis Polk advised GSK plc on the deal. GSK plc announced its acquisition of Affinivax, Inc. for a $2.1 billion upfront payment and up to $1.2 […]
PayPal’s $3 Billion Notes Offering and Concurrent Tender Offer
Skadden, Arps, Slate, Meagher & Flom advised PayPal, while Davis Polk advised the joint book-running managers and representatives of the underwriters and the dealer manager in […]
Bausch + Lomb’s $630 Million Initial Public Offering
Davis Polk advised Bausch Health Companies Inc. in connection with the separation of its eye health business into a new publicly traded company, Bausch + Lomb […]
Qualcomm’s $1.5 Billion Notes Offering
Cravath represented Qualcomm, while Davis Polk advised the representatives of the several underwriters in the offering. Qualcomm Incorporated executed its offering of $500 million aggregate principal […]
SiTime’s At-The-Market Offering
Cooley advised SiTime Corporation, while Davis Polk advised the sales agent, Stifel, Nicolaus & Company, in the offering. SiTime Corporation issued an SEC-registered at-the-market offering consisting of […]
Deciphera Pharmaceuticals’ $172.5 Million Stock and Pre-Funded Warrants Offering
Davis Polk advised the joint book-running managers, J.P. Morgan Securities LLC and Jefferie, in the offering. Deciphera Pharmaceuticals, Inc. executed a $172.5 million SEC-registered common stock and […]
Medtronic’s Acquisition of Left-Heart Access Business from Acutus
Davis Polk advised Acutus Medical on the deal. Acutus Medical, Inc. announced the sale of its left-heart access portfolio products to Medtronic, for an upfront payment of […]